Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05789069 | A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 83 | HiFiBiO TherapeuticsINDUSTRY | 3 | Jun 8, 2026 | clinicaltrials |
| NCT06322108 | Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008) | active not recruiting | Phase 2 | 45 | Immune Oncology Research InstituteOTHER | 1 | Jun 8, 2026 |
| clinicaltrials |
| NCT03132922 | MAGE-A4ᶜ¹º³²T for Multi-Tumor | active not recruiting | Phase 1 | 71 | USWM CT, LLCINDUSTRY | 2 | Jun 4, 2026 | clinicaltrials |
| NCT05161325 | A Study of Effectiveness and Safety of the First-Line Nivolumab Plus Ipilimumab With or Without Chemotherapy for Advanced/Recurrent Non-Small Cell Lung Cancer in Japan(LIGHT-NING) | active not recruiting | — | 525 | Bristol-Myers SquibbINDUSTRY | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05633667 | Study of Novel Treatment Combinations in Patients With Lung Cancer(VELOCITY-Lung) | active not recruiting | Phase 2 | 192 | Gilead SciencesINDUSTRY | 8 | Jun 1, 2026 | clinicaltrials |
| NCT05676931 | Study With Various Immunotherapy Treatments in Participants With Lung Cancer(EDGE-Lung) | active not recruiting | Phase 2 | 400 | Gilead SciencesINDUSTRY | 10 | Jun 1, 2026 | clinicaltrials |
| NCT05783622 | Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies | active not recruiting | Phase 1 | 130 | Janux TherapeuticsINDUSTRY | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04956640 | Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | active not recruiting | Phase 1 / Phase 2 | 540 | Eli Lilly and CompanyINDUSTRY | 6 | May 29, 2026 | clinicaltrials |
| NCT04514484 | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | active not recruiting | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 | clinicaltrials |
| NCT05764954 | A Study of Tumor-Treating Fields (TTFields) in People With Lung Adenocarcinoma | active not recruiting | Phase 1 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT06246110 | A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC | active not recruiting | Phase 2 | 70 | Eikon TherapeuticsINDUSTRY | 1 | May 28, 2026 | clinicaltrials |
| NCT06333951 | Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104). | active not recruiting | Phase 1 | 49 | AmgenINDUSTRY | 20 | May 28, 2026 | clinicaltrials |
| NCT05887011 | CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC and SCLC in Routine Practices in Russia(PASSAT) | active not recruiting | — | 2,000 | AstraZenecaINDUSTRY | 1 | May 27, 2026 | clinicaltrials |
| NCT04250545 | Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer | active not recruiting | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | May 26, 2026 | clinicaltrials |
| NCT05668988 | A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) | active not recruiting | Phase 3 | 324 | Dizal PharmaceuticalsINDUSTRY | 15 | May 26, 2026 | clinicaltrials |
| NCT03527108 | Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC | active not recruiting | Phase 2 | 36 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03786692 | Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC | active not recruiting | Phase 2 | 107 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06015503 | A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)(KANNON) | active not recruiting | Phase 2 | 139 | Avistone Biotechnology Co., Ltd.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT06238479 | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors(EXCEED) | active not recruiting | Phase 1 | 490 | Eli Lilly and CompanyINDUSTRY | 7 | May 22, 2026 | clinicaltrials |
| NCT02696993 | Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT04015778 | A Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China | active not recruiting | Phase 2 | 316 | Guangdong Association of Clinical TrialsOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07596433 | Tumor-informed MRD for Non-small Cell Lung Cancer | active not recruiting | — | 450 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT05096663 | Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | active not recruiting | Phase 2 / Phase 3 | 82 | SWOG Cancer Research NetworkNETWORK | 1 | May 18, 2026 | clinicaltrials |
| NCT05644808 | MYLUNG Consortium Study Protocol 2(MYLUNG) | active not recruiting | — | 1,002 | US Oncology ResearchINDUSTRY | 1 | May 18, 2026 | clinicaltrials |
| NCT03611738 | Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC | active not recruiting | Phase 1 | 21 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT04380636 | Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) | active not recruiting | Phase 3 | 870 | Merck Sharp & Dohme LLCINDUSTRY | 26 | May 15, 2026 | clinicaltrials |
| NCT04526691 | Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02) | active not recruiting | Phase 1 | 145 | Daiichi SankyoINDUSTRY | 5 | May 15, 2026 | clinicaltrials |
| NCT05462717 | Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | active not recruiting | Phase 1 | 222 | Revolution Medicines, Inc.INDUSTRY | 13 | May 15, 2026 | clinicaltrials |
| NCT05653752 | A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer | active not recruiting | Phase 1 | 80 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 2 | May 15, 2026 | clinicaltrials |
| NCT06606847 | A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)(LADOGA) | active not recruiting | Phase 2 | 30 | AstraZenecaINDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT03807778 | A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer | active not recruiting | Phase 1 | 53 | TakedaINDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT06946797 | A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)(CheckMate-1533) | active not recruiting | Phase 2 | 76 | Bristol-Myers SquibbINDUSTRY | 9 | May 14, 2026 | clinicaltrials |
| NCT04314401 | National Cancer Institute "Cancer Moonshot Biobank" | active not recruiting | — | 1,600 | National Cancer Institute (NCI)NIH | 2 | May 13, 2026 | clinicaltrials |
| NCT02998567 | Combination Study of Guadecitabine/ASTX727 and Pembrolizumab(HyPeR) | active not recruiting | Phase 1 | 60 | Royal Marsden NHS Foundation TrustOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT03819465 | A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC(MAGELLAN) | active not recruiting | Phase 1 | 175 | AstraZenecaINDUSTRY | 9 | May 12, 2026 | clinicaltrials |
| NCT07485179 | Emulation of the KEYNOTE-042 (NCT02220894) Trial Using Specialty Oncology Electronic Health Records Databases | active not recruiting | — | 770 | Brigham and Women's HospitalOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT04716946 | Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy | active not recruiting | Phase 2 | 13 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT04940936 | Shared Decision Making on Radiation Dose for Lung Malignancies | active not recruiting | N/A | 40 | Vejle HospitalOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05615142 | Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC. | active not recruiting | Phase 1 | 9 | Sichuan UniversityOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT03202940 | A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC | active not recruiting | Phase 1 / Phase 2 | 16 | Massachusetts General HospitalOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT05870319 | A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients | active not recruiting | Phase 3 | 376 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT06448312 | A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | active not recruiting | Phase 3 | 406 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT07485166 | Emulation of the CheckMate 017/057 (NCT01642004 and NCT01673867) Trials Using Specialty Oncology Electronic Health Records Databases | active not recruiting | — | 810 | Brigham and Women's HospitalOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT05089734 | Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)(EVOKE-01) | active not recruiting | Phase 3 | 603 | Gilead SciencesINDUSTRY | 20 | May 7, 2026 | clinicaltrials |
| NCT02417662 | Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer(SARON) | active not recruiting | N/A | 140 | University College, LondonOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05557591 | A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1) | active not recruiting | Phase 2 | 51 | Regeneron PharmaceuticalsINDUSTRY | 7 | May 6, 2026 | clinicaltrials |
| NCT04430725 | Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME Study | active not recruiting | — | 74 | M.D. Anderson Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04564157 | New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy(NADIM-ADJUVANT) | active not recruiting | Phase 3 | 210 | Fundación GECPOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05012254 | Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases(NIVIPI-Brain) | active not recruiting | Phase 2 | 71 | Fundación GECPOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05138900 | A Pilot Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) in Central Non-Small Cell Lung Cancer | active not recruiting | N/A | 30 | Roswell Park Cancer InstituteOTHER | 1 | May 5, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 8, 2026source: clinicaltrials